| Literature DB >> 27382053 |
Xu Feng1, Peng Liu1, Xin Zhou1, Meng-Tian Li1, Fu-Long Li1, Zhen Wang1, Zhipeng Meng2, Yi-Ping Sun1, Ying Yu3, Yue Xiong4, Hai-Xin Yuan5, Kun-Liang Guan6.
Abstract
The thromboxane A2 receptor (TP) has been implicated in restenosis after vascular injury, which induces vascular smooth muscle cell (VSMC) migration and proliferation. However, the mechanism for this process is largely unknown. In this study, we report that TP signaling induces VSMC migration and proliferation through activating YAP/TAZ, two major downstream effectors of the Hippo signaling pathway. The TP-specific agonists [1S-[1α,2α(Z),3β(1E,3S*),4 α]]-7-[3-[3-hydroxy-4-(4-iodophenoxy)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (I-BOP) and 9,11-dideoxy-9α,11α-methanoepoxy-prosta-5Z,13E-dien-1-oic acid (U-46619) induce YAP/TAZ activation in multiple cell lines, including VSMCs. YAP/TAZ activation induced by I-BOP is blocked by knockout of the receptor TP or knockdown of the downstream G proteins Gα12/13 Moreover, Rho inhibition or actin cytoskeleton disruption prevents I-BOP-induced YAP/TAZ activation. Importantly, TP activation promotes DNA synthesis and cell migration in VSMCs in a manner dependent on YAP/TAZ. Taken together, thromboxane A2 signaling activates YAP/TAZ to promote VSMC migration and proliferation, indicating YAP/TAZ as potential therapeutic targets for cardiovascular diseases.Entities:
Keywords: G protein-coupled receptor (GPCR); Hippo pathway; TAZ; cell migration; thromboxane A2; vascular smooth muscle cells; yes-associated protein (YAP)
Mesh:
Substances:
Year: 2016 PMID: 27382053 PMCID: PMC5009267 DOI: 10.1074/jbc.M116.739722
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157